Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
McKinsey
Healthtrust
Daiichi Sankyo
Colorcon
AstraZeneca
Boehringer Ingelheim
Argus Health
Deloitte

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,204,763

« Back to Dashboard

Which drugs does patent 8,204,763 protect, and when does it expire?

Patent 8,204,763 protects POMALYST, REVLIMID, and THALOMID, and is included in three NDAs.
Summary for Patent: 8,204,763
Title:Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Abstract: Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
Inventor(s): Elsayed; Marc (Bridgewater, NJ), Williams; Bruce (Flemington, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:12/966,240
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,204,763

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-001 Feb 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE ➤ Subscribe
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-002 Feb 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE ➤ Subscribe
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-003 Feb 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE ➤ Subscribe
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-004 Feb 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE ➤ Subscribe
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-005 Dec 21, 2011 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG ➤ Subscribe
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-001 Dec 27, 2005 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG ➤ Subscribe
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-002 Dec 27, 2005 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG ➤ Subscribe
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG ➤ Subscribe
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-006 Jun 5, 2013 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG ➤ Subscribe
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,204,763

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,874,984 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Subscribe
6,045,501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Subscribe
6,561,976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Subscribe
8,589,188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Subscribe
6,908,432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Subscribe
6,767,326 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Citi
Colorcon
US Department of Justice
AstraZeneca
US Army
Queensland Health
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot